Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

Taking steps now — no matter how small — provides far greater benefits than managing heart disease later. Here are eight ...

Long-term exposure to common air pollutants is associated with more advanced coronary artery disease-with notable differences ...

Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

Many drugs available and in development work by targeting proteins, an approach that comes with limitations. For one, proteins are not the root cause of disease, said Samir Ounzain, co-founder and CEO ...

Myqorzo and Redemplo approved in ChinaApproval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia ...

China NMPA approves Sanofi’s Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome: Paris Saturday, January 17, 2026, 11:00 Hrs ...